Injectable GHK-Cu in 2026: reclassified in April, absent from the July vote - where it actually stands

TL;DR

• GHK-Cu was never classified as one substance - it was classified by route - injectable sat in 503A Category 2, non-injectable (topical) in Category 1.
• The 2026 action removed each route from its respective category - Category 2 removals took effect 23 April 2026, following a Federal Register notice published 16 April 2026.
• Category 1 is not approval - it carries no validated indications, no standardised dosing, and no established safety or efficacy record.
• GHK-Cu was not on the July 2026 PCAC agenda - that vote covered a different set of seven peptides, six recommended and emideltide (DSIP) the sole rejection.
• Injectable GHK-Cu is queued for a second PCAC review expected before the end of February 2027, with no exact date posted; what replaced its Category 2 position is a pending review, not permission.
• Do not assume the October interim policy covers GHK-Cu - an FDA/HHS "Interim Access Policy for Compounding Using Certain Peptides" went to White House (OMB) review on 14 October 2026, but it has not been issued, its text is not public, and GHK-Cu is on the second docket, not among the six recommended in July.
• Topical GHK-Cu continues as a cosmetic ingredient on a separate track, while the injectable route stays investigational and physician-supervised only.

Educational content, not medical advice. No doses or protocols appear anywhere; any use is physician-directed. Injectable GHK-Cu is investigational and not FDA-approved.

Updated October 2026: adds the 14 October 2026 submission of an FDA/HHS interim peptide compounding policy to OMB review (not issued, text not public, coverage unknown) and states that GHK-Cu, as a second-docket peptide rather than one of the six recommended in July, should not be assumed covered. Status as of 19 October 2026.

Updated September 2026 - factual correction: this page previously stated that injectable GHK-Cu was "removed from the 503A Category 2 list on 15 April 2026" and framed GHK-Cu's status as a single-substance question. Both have been corrected. GHK-Cu was categorised by route - injectable in Category 2, non-injectable (topical) in Category 1 - and the 2026 action removed each route from its respective category. The Category 2 removals took effect 23 April 2026, following a Federal Register notice published 16 April 2026. The page now also states plainly that Category 1 is not approval, and that what replaced injectable GHK-Cu's old Category 2 position is not permission - it is a pending review before a second PCAC meeting expected before the end of February 2027, with no exact date posted. Matches the framing in the second PCAC docket page.

Updated August 2026: the April Category 2 removal is now dated precisely [superseded - see the correction note above; the correct dates are a 16 April 2026 notice with removals effective 23 April 2026], and the July PCAC outcome is confirmed at six of seven recommended with emideltide/DSIP the sole rejection - none of which covered GHK-Cu.

---

The GHK-Cu story in 2026 is a case study in why "is this legal now?" is almost always the wrong question about peptides - the honest answer depends on the form, the route, and which of several parallel FDA processes you're actually asking about. Here is the accurate map.

Two different regulatory tracks: the April 2026 removal vs the July PCAC agenda

The confusion is understandable, because two separate FDA actions happened months apart and get mentally merged into one "peptide crackdown."

In April 2026, following a Federal Register notice published 16 April 2026, the FDA cleared a batch of peptides out of its Section 503A Category 2 list, with the removals taking effect 23 April 2026. Category 2 was, in effect, a holding pen: substances the agency had flagged with potential safety questions (for injectable GHK-Cu, concerns cited around immunogenicity and impurities) while it decided what to do with them.

And here is the detail that almost every summary drops. GHK-Cu was never categorised as a single substance - it was categorised by route.

• Injectable GHK-Cu sat in Category 2 - substances raising significant safety concerns.
• Non-injectable (topical) GHK-Cu sat in Category 1.

The 2026 action removed each route from its respective category in the same sweep. The injectable form came off Category 2; the topical form came off Category 1. That is why coverage treating GHK-Cu as one item ends up contradicting itself depending on which route the underlying source was describing - and it is why this page previously carried a single-substance framing that has now been corrected.

On the size of that sweep, two figures circulate and they do not reconcile. The 27 February 2026 HHS announcement by Secretary Robert F. Kennedy Jr. described roughly 14 of 19 peptides moving; FDA's published action covered 12 peptides removed from Category 2. Rather than pick a side, the accurate summary is the one both figures support: the Category 2 list was cleared of most of the peptides on it.

Removal from Category 2 is a procedural step, not a verdict - it lifts an explicit prohibition, and critically it does not by itself place a compound on the 503A Bulk Drug Substances List that governs what pharmacies may legally compound. Listing is the requirement; removal from Category 2 is merely the removal of a barrier to being considered.

Then, on 23–24 July 2026, the Pharmacy Compounding Advisory Committee (PCAC) met to vote on a different set of seven peptides - BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon, and emideltide (DSIP) - for possible addition to the 503A bulks list. Six were recommended; emideltide was the only rejection. GHK-Cu was not on that agenda at all. The two events are related in spirit and separate in mechanism, which is exactly why coverage that lumped them together left GHK-Cu users confused about where their compound landed. Worth noting on that vote, because it calibrates how much a favourable committee outcome is worth: FDA's own career scientists recommended against adding any of the seven, and the committee recommended six anyway. The full account is in the FDA vote recap.

Category 1 is not approval. It is not even close.

This is the sentence that matters most on this page, so it gets its own line.

Coming off Category 2, being reviewed for the 503A list, and FDA approval are three entirely different things. Category 1 status is a statement about where a substance sits in a compounding framework - nothing more. It carries no validated indications, no standardised dosing, no established safety record and no established efficacy record. A substance can sit in Category 1 with no completed human trials behind it at all. Reading a category change as a clinical green light is the single most common error in this story, and it is the error this page exists to prevent.

And what replaced injectable GHK-Cu's old Category 2 position is not permission - it is a pending review. GHK-Cu goes in front of a second PCAC meeting. That meeting has not happened, no exact date for it has been posted, and the committee that will hold it is advisory. The honest status line is: previously restricted, now unrestricted in that one specific procedural sense, currently queued for scrutiny, still not approved for anything.

Why GHK-Cu wasn't among the seven voted peptides

The short version: GHK-Cu was already moving through its own pipeline, on a different timeline. Rather than being folded into the July docket, injectable GHK-Cu sits in the second wave of PCAC review, which the FDA has indicated will be convened before the end of February 2027 - a separate cycle from the seven peptides voted on this summer. That later docket is reported to cover five compounds: LL-37, GHK-Cu, Dihexa acetate, Melanotan II, and PEG-MGF. The FDA has not posted a final date, time or comment docket for it - "before the end of February 2027" is the expectation reported by legal trackers, not a calendar entry, and any specific date you see quoted should be treated as unverified until the FDA's primary notice appears. So the July silence on GHK-Cu wasn't a rejection or an oversight; it was a scheduling artifact of an agency working through a long queue of compounds one tranche at a time. (When that meeting lands, expect the same wave of "is it legal now?" confusion the July vote produced - the antidote is the three-status timeline.)

Where GHK-Cu sits in the "three-status" picture

The broader 2026 confusion is that three different legal statuses - reclassified, recommended, approved - keep getting collapsed into one. (A fourth, listed, sits between the second and the third: a substance is only actually on the 503A Bulks List once rulemaking completes.) GHK-Cu is a clean illustration of why the distinction matters. Injectable GHK-Cu was part of the April 2026 Category 2 removal - it came off Category 2, effective 23 April 2026 - but it was not among the six recommended by the July advisory vote, it is not listed, and it is certainly not approved. It occupies, in effect, the space between the first status and the second, awaiting its own review. Untangling those three statuses across the whole category is the job of are peptides legal now? the 2026 timeline; this article is the GHK-Cu-specific slice of it.

October 2026: the interim policy, and why GHK-Cu should not be assumed in it

On 14 October 2026 HHS and the FDA submitted a document titled "Interim Access Policy for Compounding Using Certain Peptides" to the Office of Information and Regulatory Affairs at the White House Office of Management and Budget. As of 19 October 2026 it is pending review, has not been issued, and its text is not public, so which substances, routes and conditions it covers is unknown. Press coverage has linked it to the peptides the committee recommended in July, such as BPC-157. GHK-Cu is not one of those six: it is on the second docket, which has not been voted on. Nothing published so far says the interim policy reaches injectable GHK-Cu, and it should not be assumed to. Law firms expect, if issued, a temporary enforcement-discretion posture for 503A pharmacies, which would approve nothing, add nothing to the 503A Bulks List, and could be withdrawn without notice-and-comment.

What "not approved, not on the July list" means for access

Practically, less changed than the headlines around either event implied.

Injectable GHK-Cu was not FDA-approved before April, and it is not FDA-approved now. Coming off Category 2 did not make it a listed, compoundable substance, and its absence from the July vote means it has no advisory-committee recommendation one way or the other yet. The compound therefore sits in a regulatory gray area: not blessed, not formally listed, awaiting a review that hasn't happened and has no posted date. For anyone tracking this to time a purchase, the practical takeaway is the one that survives every news cycle - a compound's shifting category is not a statement about safety, and the question of whether it belongs anywhere near you is a clinical one for a prescriber, not a regulatory one you can settle from a headline.

Topical vs injectable: the legality and evidence split

This is the distinction that matters most and is most often collapsed.

Topical GHK-Cu - the copper tripeptide in serums and creams - is a long-established cosmetic ingredient with a genuine dermatology evidence base for skin appearance and repair signaling. As a compounding matter it sat in Category 1, and it came off Category 1 in the same 2026 sweep that took the injectable off Category 2 - which is the whole point of the by-route framing, and the reason "GHK-Cu was reclassified" is an ambiguous sentence unless you say which route you mean. Injectable / systemic GHK-Cu is the investigational one: it's the route that carried the Category 2 safety flags, and it's the one in the compounding queue. The evidence base thins dramatically as you move from topical cosmetic use to systemic injection, and so does the regulatory clarity. Our topical-vs-injectable GHK-Cu guide walks through how delivery route changes both what to expect and what the data supports, and the broader injectable-vs-topical peptides-for-skin explainer covers the same split across the category.

Why a category change is not a buying signal

Transitional regulatory moments are exactly when the grey market gets loudest - "reclassified, get it before the rules land" is a sales pitch, not a safety assurance, and it will get louder as the second PCAC meeting approaches. A compound moving between FDA categories does not change a single physical property of what is in a vial, and the immunogenicity and impurity concerns that put injectable GHK-Cu in Category 2 in the first place have not been resolved by its removal from that category - the category moved, the questions did not.

We are not going to hand you a checklist for grading sellers. That exercise reads as a specification to the people it is meant to warn you about, and it puts the burden in the wrong place: on the person with the least information and the most to lose. The durable answer is the boring one - work inside a supervised channel and route the question to a prescriber who can take clinical responsibility for what you are given, screen the cautions that apply to you, and read this evidence at its real weight. For the wider legal picture across the category, see which peptides are legal in 2026.

Frequently asked questions

Is injectable GHK-Cu still on compounding Category 2? No - and earlier versions of this page framed the question as if GHK-Cu had one category. It did not. GHK-Cu was categorised by route: the injectable form sat in Category 2, the non-injectable (topical) form sat in Category 1. The 2026 action removed each route from its respective category, with the Category 2 removals effective 23 April 2026, following a Federal Register notice published 16 April 2026.

Does that mean injectable GHK-Cu is approved, or safe to use? No. Category 1 is not approval. It carries no validated indications, no standardised dosing, and no established safety or efficacy record. Coming off Category 2, being reviewed for the 503A list, and FDA approval are three different things, and GHK-Cu has only done the first. What replaced its old Category 2 position is not permission - it is a pending review in front of a second PCAC meeting that has not happened and has no posted date. Any use is a conversation with a prescriber, not a conclusion drawn from a category change.

Is injectable GHK-Cu legal right now? It is not FDA-approved, and coming off 503A Category 2 did not place it on the 503A Bulk Drug Substances List - the list that actually governs lawful compounding. Listing would require HHS Secretary sign-off and notice-and-comment rulemaking, neither of which has happened for GHK-Cu. It sits in a regulatory gray area pending a second-wave PCAC review expected before the end of February 2027, with no exact date posted. Its status did not change with the July 2026 vote, which didn't cover it.

Was GHK-Cu banned or freed by the 2026 changes? Neither, cleanly. Coming off Category 2 lifts an explicit prohibition on the injectable route; it is not an approval and not a listing. Injectable GHK-Cu remains investigational and awaits its own committee review.

How many peptides came off Category 2? Two figures circulate. The February 2026 HHS announcement described roughly 14 of 19 peptides moving; FDA's published action covered 12 peptides removed from Category 2. The statement both support is that the Category 2 list was cleared of most of the peptides on it.

Is topical GHK-Cu safer or more legal than the injectable? Topical GHK-Cu is a long-established cosmetic ingredient on a separate regulatory track with a real dermatology evidence base. The injectable/systemic route is the investigational one carrying the safety flags and the compounding-queue uncertainty.

Should I wait for the PCAC review before considering it? Any decision about an investigational compound belongs with a physician, not a regulatory calendar. A future committee vote - like July's - would be advisory anyway, and would still require FDA rulemaking before anything about lawful access actually changed.

Related reading

• Do copper peptides (GHK-Cu) actually work? · GHK-Cu: topical vs injectable (and microneedling) · GHK-Cu: the repair signal, not the "beauty peptide" · Are peptides legal now? The 2026 timeline · How to choose a trustworthy peptide source · The 5 peptides on the second PCAC docket
• Part of The Evidence-Based Guide to Looksmaxxing

---

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore GHK-Cu.

---

Educational content, not medical advice. Injectable GHK-Cu is investigational and not FDA-approved; coming off 503A Category 2 is procedural and does not authorise compounding or retail sale. Category 1 is not approval, and reviewed is not approved. Any use is physician-directed; do not self-source peptides. Claims for the Malaysian market are subject to MAB requirements. This article reflects the regulatory picture as of 19 October 2026 and will be updated as the FDA acts.

References

• GHK-Cu was categorised by route: injectable GHK-Cu in Section 503A Category 2, non-injectable (topical) GHK-Cu in Category 1. The 2026 action removed each route from its respective category. Category 2 removals took effect 23 April 2026, per a Federal Register notice published 16 April 2026. Sources: Orrick (April 2026); Pharmacy Times. An earlier version of this page dated the removal to 15 April 2026 and treated GHK-Cu as a single-category substance; both have been corrected.
• Scale of the sweep: the 27 February 2026 HHS announcement described roughly 14 of 19 peptides moving; FDA's published action covered 12 peptides removed from Category 2. The two figures do not reconcile - prefer "the Category 2 list was cleared of most of the peptides on it," or state both with attribution.
• Category 1 is explicitly not approval: no validated indications, no standardised dosing, no established safety or efficacy record. Removal from Category 2, review for the 503A list, and FDA approval are three separate states; listed (after rulemaking) is a fourth.
• GHK-Cu had been placed in Category 2 over immunogenicity and impurity concerns. Coming off Category 2 is not an FDA drug approval and does not, by itself, add a substance to the 503A Bulk Drug Substances List; listing requires HHS Secretary sign-off and notice-and-comment rulemaking.
• GHK-Cu was not among the seven peptides reviewed at the 23–24 July 2026 PCAC meeting, at which six of seven were recommended and emideltide (DSIP) was the sole rejection. FDA's career scientists recommended against all seven; the committee recommended six anyway. As of 4 September 2026 there is still no final rule. Sources: AJMC; NCPA (31 July 2026); Health Affairs Forefront; FDA briefing document; RAPS.
• A second PCAC meeting is expected before the end of February 2027, reported to cover five compounds: LL-37, GHK-Cu, Dihexa acetate, Melanotan II, and PEG-MGF. No exact date has been posted - do not cite one until the FDA's primary notice appears.
• Interim policy: HHS/FDA submitted "Interim Access Policy for Compounding Using Certain Peptides" to OIRA/OMB for review on 14 October 2026; pending review, not issued, text not public as of 19 October 2026; covered substances unknown; likely mechanism enforcement discretion (law-firm analysis, not an FDA statement). GHK-Cu remains on the second docket and is not among the six July recommendations. Sources: Buchanan Ingersoll & Rooney (16 October 2026) https://www.bipc.com/fda-submits-interim-peptide-compounding-policy-for-white-house-review-what-pharmacies-should-know · Holland & Knight, "Peptides at a Crossroads" (October 2026) https://www.hklaw.com/en/insights/publications/2026/10/peptides-at-a-crossroads-what-wellness-providers-need-to-know
• Topical GHK-Cu regulated as a cosmetic ingredient on a distinct track. · Background dermatology evidence: Pickart L, Margolina A. Biomed Res Int. 2015;2015:648108. · Reporting/analysis: Boesen & Snow Law, McDermott, Newtropin and BSR peptide status trackers (2026). Re-verify the second-docket compound list and meeting date against the FDA advisory-committee calendar before publication.

Regulatory sources are secondary summaries. The FDA's Federal Register notice and PCAC meeting materials are the primary record and should be consulted directly when published.